Telix Advances China Market Entry for Illuccix Prostate Cancer Imaging
Telix Pharmaceuticals Limited (ASX: TLX) has reached a key regulatory milestone with the acceptance of a New Drug Application by China’s National Medical Products Administration for Illuccix®, its lead prostate cancer imaging agent. Filed in partnership with Grand Pharmaceutical Group, the application is supported by positive results from a Phase 3 China registration study, which demonstrated a high diagnostic accuracy in detecting recurrent prostate cancer. The study showed strong clinical utility across patient subgroups, including those with low PSA levels, and materially influenced treatment decisions in a majority of cases. Acceptance of the application marks Telix’s first regulatory filing in China and aligns with its strategy to expand geographically in precision medicine. With prostate cancer incidence rising and nuclear medicine infrastructure expanding rapidly in China, regulatory progress for Illuccix positions Telix to address a growing unmet clinical need while strengthening its global footprint in radiopharmaceutical diagnostics.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
Telix Advances China Market Entry for Illuccix Prostate Cancer Imaging
Telix Pharmaceuticals Limited (ASX: TLX) has reached a key regulatory milestone with the acceptance of a New Drug Application by China’s National Medical Products Administration for Illuccix®, its lead prostate cancer imaging agent. Filed in partnership with Grand Pharmaceutical Group, the application is supported by positive results from a Phase 3 China registration study, which demonstrated a high diagnostic accuracy in detecting recurrent prostate cancer. The study showed strong clinical utility across patient subgroups, including those with low PSA levels, and materially influenced treatment decisions in a majority of cases. Acceptance of the application marks Telix’s first regulatory filing in China and aligns with its strategy to expand geographically in precision medicine. With prostate cancer incidence rising and nuclear medicine infrastructure expanding rapidly in China, regulatory progress for Illuccix positions Telix to address a growing unmet clinical need while strengthening its global footprint in radiopharmaceutical diagnostics.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au